Plasmacytoid dendritic cells lead the charge against tumors

Sonia Jiménez-Baranda; Inês Pires Silva; Nina Bhardwaj

doi:10.1172/JCI61345

Plasmacytoid dendritic cells lead the charge against tumors

Sonia Jiménez-Baranda
, Inês Pires Silva
, Nina Bhardwaj

Research output: Contribution to journal › Comment/debate

4 Scopus citations

Abstract

Imiquimod is a TLR agonist that is used as an antitumor agent, mainly against skin tumors. Its clinical benefits are well described in several studies; however, the mechanisms behind its antitumor effects are not completely understood. In this issue of the JCI, Drobits and colleagues demonstrate that topical application of imiquimod suppresses cutaneous melanoma by TLR7-dependent recruitment and transformation of plasmacytoid dendritic cells into killer cells; this occurs independently of conventional adaptive immune mechanisms.

Original language	English
Pages (from-to)	481-484
Number of pages	4
Journal	Journal of Clinical Investigation
Volume	122
Issue number	2
DOIs	https://doi.org/10.1172/JCI61345
State	Published - Feb 2012
Externally published	Yes

Access to Document

10.1172/JCI61345

Cite this

@article{8a434b1811254db1a21d484a3c71c946,

title = "Plasmacytoid dendritic cells lead the charge against tumors",

abstract = "Imiquimod is a TLR agonist that is used as an antitumor agent, mainly against skin tumors. Its clinical benefits are well described in several studies; however, the mechanisms behind its antitumor effects are not completely understood. In this issue of the JCI, Drobits and colleagues demonstrate that topical application of imiquimod suppresses cutaneous melanoma by TLR7-dependent recruitment and transformation of plasmacytoid dendritic cells into killer cells; this occurs independently of conventional adaptive immune mechanisms.",

author = "Sonia Jim{\'e}nez-Baranda and Silva, \{In{\^e}s Pires\} and Nina Bhardwaj",

year = "2012",

month = feb,

doi = "10.1172/JCI61345",

language = "English",

volume = "122",

pages = "481--484",

journal = "Journal of Clinical Investigation",

issn = "0021-9738",

publisher = "American Society for Clinical Investigation",

number = "2",

}

TY - JOUR

T1 - Plasmacytoid dendritic cells lead the charge against tumors

AU - Jiménez-Baranda, Sonia

AU - Silva, Inês Pires

AU - Bhardwaj, Nina

PY - 2012/2

Y1 - 2012/2

N2 - Imiquimod is a TLR agonist that is used as an antitumor agent, mainly against skin tumors. Its clinical benefits are well described in several studies; however, the mechanisms behind its antitumor effects are not completely understood. In this issue of the JCI, Drobits and colleagues demonstrate that topical application of imiquimod suppresses cutaneous melanoma by TLR7-dependent recruitment and transformation of plasmacytoid dendritic cells into killer cells; this occurs independently of conventional adaptive immune mechanisms.

AB - Imiquimod is a TLR agonist that is used as an antitumor agent, mainly against skin tumors. Its clinical benefits are well described in several studies; however, the mechanisms behind its antitumor effects are not completely understood. In this issue of the JCI, Drobits and colleagues demonstrate that topical application of imiquimod suppresses cutaneous melanoma by TLR7-dependent recruitment and transformation of plasmacytoid dendritic cells into killer cells; this occurs independently of conventional adaptive immune mechanisms.

UR - https://www.scopus.com/pages/publications/84856552035

U2 - 10.1172/JCI61345

DO - 10.1172/JCI61345

M3 - Comment/debate

C2 - 22251700

AN - SCOPUS:84856552035

SN - 0021-9738

VL - 122

SP - 481

EP - 484

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

IS - 2

ER -

Plasmacytoid dendritic cells lead the charge against tumors

Abstract

Access to Document

Fingerprint

Cite this